Functional selectivity of 6′-guanidinonaltrindole (6′-GNTI) at κ-opioid receptors in striatal neurons

Journal of Biological Chemistry

Volumn 288, Issue 31, 2013, Pages 22387-22398

  Schmid, Cullen L ^a   Streicher, John M ^a,d   Groer, Chad E ^a,e   Munro, Thomas A ^b,c   Zhou, Lei ^a   Bohn, Laura M ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MCLEAN HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF NEW ENGLAND   (United States)

^e Mencuro Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN; OPIOID RECEPTORS; SIGNALING PATHWAYS; STRIATAL NEURONS; TRANSFECTED CELLS;

PROTEINS;

NEURONS;

6' GUANIDINONALTRINDOLE; BETA ARRESTIN; GUANINE NUCLEOTIDE BINDING PROTEIN; KAPPA OPIATE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NALTRINDOLE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE TRANSLOCATION; INTERNALIZATION; MOUSE; NERVE CELL; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; STRIATAL NEURON; STRIATE CORTEX;

Κ-OPIOID RECEPTOR; ARRESTIN; BRAIN; DRUG SCREENING; G PROTEIN-COUPLED RECEPTORS (GPCR); GENE KNOCKOUT; MAP KINASES (MAPKS); NEURONS; OPIATE OPIOID; RECEPTOR ENDOCYTOSIS;

ANIMALS; CHO CELLS; CORPUS STRIATUM; CRICETINAE; CRICETULUS; GUANIDINES; MALE; MAP KINASE SIGNALING SYSTEM; MICE; NALTREXONE; NEURONS; PHOSPHORYLATION; RECEPTORS, OPIOID, KAPPA;

EID: 84881236758     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.476234     Document Type: Article

References (41)

1. Glick, S. D., Maisonneuve, I. M., Raucci, J., and Archer, S. (1995) Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res. 681, 147-152
2. Negus, S. S., Mello, N. K., Portoghese, P. S., and Lin, C. E. (1997) Effects of kappa opioids on cocaine self-administration by rhesus monkeys. J. Pharmacol. Exp. Ther. 282, 44-55
3. Schenk, S., Partridge, B., and Shippenberg, T. S. (1999) U69593, a kappaopioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug seeking. Psychopharmacology (Berl.) 144, 339-346
4. Potter, D. N., Damez-Werno, D., Carlezon, W. A., Jr., Cohen, B. M., and Chartoff, E. H. (2011) Repeated exposure to the kappa-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity. Biol. Psychiatry 70, 744-753
5. Van't Veer, A., Bechtholt, A. J., Onvani, S., Potter, D., Wang, Y., Liu-Chen, L. Y., Schütz, G., Chartoff, E. H., Rudolph, U., Cohen, B. M., and Carlezon, W. A., Jr. (2013) Ablation of kappa-opioid receptors from brain dopamine neurons has anxiolytic-like effects and enhances cocaine-induced plasticity. Neuropsychopharmacology 38, 1585-1597
6. Carlezon, W. A., Jr., Béguin, C., DiNieri, J. A., Baumann, M. H., Richards, M. R., Todtenkopf, M. S., Rothman, R. B., Ma, Z., Lee, D. Y., and Cohen, B. M. (2006) Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J. Pharmacol. Exp. Ther. 316, 440-447
7. Cohen, B. M., and Murphy, B. (2008) The effects of pentazocine, a kappa agonist, in patients with mania. Int. J. Neuropsychopharmacol. 11, 243-247
8. Walsh, S. L., Geter-Douglas, B., Strain, E. C., and Bigelow, G. E. (2001) Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans. J. Pharmacol. Exp. Ther. 299, 147-158
9. Bodkin, J. A., Zornberg, G. L., Lukas, S. E., and Cole, J. O. (1995) Buprenorphine treatment of refractory depression. J. Clin. Psychopharmacol. 15, 49-57
10. Mague, S. D., Pliakas, A. M., Todtenkopf, M. S., Tomasiewicz, H. C., Zhang, Y., Stevens, W. C., Jr., Jones, R. M., Portoghese, P. S., and Carlezon, W. A., Jr. (2003) Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J. Pharmacol. Exp. Ther. 305, 323-330
11. Knoll, A. T., Muschamp, J. W., Sillivan, S. E., Ferguson, D., Dietz, D. M., Meloni, E. G., Carroll, F. I., Nestler, E. J., Konradi, C., and Carlezon, W. A., Jr. (2011) Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats. Biol. Psychiatry 70, 425-433
12. Land, B. B., Bruchas, M. R., Schattauer, S., Giardino, W. J., Aita, M., Messinger, D., Hnasko, T. S., Palmiter, R. D., and Chavkin, C. (2009) Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. Proc. Natl. Acad. Sci. U.S.A. 106, 19168-19173
13. Aldrich, J. V., Patkar, K. A., and McLaughlin, J. P. (2009) Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action. Proc. Natl. Acad. Sci. U.S.A. 106, 18396-18401
14. Broadbear, J. H., Negus, S. S., Butelman, E. R., de Costa, B. R., and Woods, J. H. (1994) Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay. Psychopharmacology (Berl.) 115, 311-319
15. Ko, M. C., Willmont, K. J., Lee, H., Flory, G. S., and Woods, J. H. (2003) Ultra-long antagonism of kappa opioid agonist-induced diuresis by intracisternal norbinaltorphimine in monkeys. Brain Res. 982, 38-44
16. Kenakin, T. (2007) Functional selectivity through protean and biased agonism: who steers the ship? Mol. Pharmacol. 72, 1393-1401
17. Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., Miller, K. J., Spedding, M., and Mailman, R. B. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320, 1-13
18. Schmid, C. L., and Bohn, L. M. (2010) Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ss-arrestin2/Src/Akt signaling complex in vivo. J. Neurosci. 30, 13513-13524
19. Raehal, K. M., Schmid, C. L., Groer, C. E., and Bohn, L. M. (2011) Functional selectivity at the mu-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol. Rev. 63, 1001-1019
20. Mailman, R. B. (2007) GPCR functional selectivity has therapeutic impact. Trends Pharmacol. Sci. 28, 390-396
21. McLennan, G. P., Kiss, A., Miyatake, M., Belcheva, M. M., Chambers, K. T., Pozek, J. J., Mohabbat, Y., Moyer, R. A., Bohn, L. M., and Coscia, C. J. (2008) Kappa opioids promote the proliferation of astrocytes via Gbetagamma and beta-arrestin 2-dependent MAPK-mediated pathways. J. Neurochem. 107, 1753-1765
22. Bruchas, M. R., Yang, T., Schreiber, S., Defino, M., Kwan, S. C., Li, S., and Chavkin, C. (2007) Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. J. Biol. Chem. 282, 29803-29811
23. Negri, A., Rives, M. L., Caspers, M. J., Prisinzano, T. E., Javitch, J. A., and Filizola, M. (2013) Discovery of a novel selective kappa-opioid receptor agonist using crystal structure-based virtual screening. J. Chem. Inf. Model. 53, 521-526
24. Spetea, M., Asim, M. F., Noha, S., Gerhard, G., and Schmidhammer, H. (2013) Current kappa opioid receptor ligands and discovery of a new molecular scaffold as a kappa opioid receptor antagonist using pharmacophore-based virtual screening. Curr. Pharm. Des., in press
25. Wu, H., Wacker, D., Mileni, M., Katritch, V., Han, G. W., Vardy, E., Liu, W., Thompson, A. A., Huang, X. P., Carroll, F. I., Mascarella, S. W., Westkaemper, R. B., Mosier, P. D., Roth, B. L., Cherezov, V., and Stevens, R. C. (2012) Structure of the human kappa-opioid receptor in complex with JDTic. Nature 485, 327-332
26. Sharma, S. K., Jones, R. M., Metzger, T. G., Ferguson, D. M., and Portoghese, P. S. (2001) Transformation of a kappa-opioid receptor antagonist to a kappa-agonist by transfer of a guanidinium group from the 5'-to 6'-position of naltrindole. J. Med. Chem. 44, 2073-2079
27. Rives, M. L., Rossillo, M., Liu-Chen, L. Y., and Javitch, J. A. (2012) 6'-Guanidinonaltrindole (6'-GNTI) is a G protein-biased κ-opioid receptor agonist that inhibits arrestin recruitment. J. Biol. Chem. 287, 27050-27054
28. Bohn, L. M., Lefkowitz, R. J., Gainetdinov, R. R., Peppel, K., Caron, M. G., and Lin, F. T. (1999) Enhanced morphine analgesia in mice lacking betaarrestin 2. Science 286, 2495-2498
29. Bohn, L. M., Dykstra, L. A., Lefkowitz, R. J., Caron, M. G., and Barak, L. S. (2004) Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery. Mol. Pharmacol. 66, 106-112
30. Groer, C. E., Tidgewell, K., Moyer, R. A., Harding, W. W., Rothman, R. B., Prisinzano, T. E., and Bohn, L. M. (2007) An opioid agonist that does not induce mu-opioid receptor-arrestin interactions or receptor internalization. Mol. Pharmacol. 71, 549-557
31. Schmid, C. L., Raehal, K. M., and Bohn, L. M. (2008) Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc. Natl. Acad. Sci. U.S.A. 105, 1079-1084
32. Black, J. W., and Leff, P. (1983) Operational models of pharmacological agonism. Proc. R. Soc. Lond. B Biol. Sci. 220, 141-162
33. Kenakin, T., and Christopoulos, A. (2013) Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat. Rev. Drug Discov. 12, 205-216
34. Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A., and Novick, S. (2012) A simple method for quantifying functional selectivity and agonist bias. ACS Chem. Neurosci. 3, 193-203
35. Evans, B. A., Broxton, N., Merlin, J., Sato, M., Hutchinson, D. S., Christopoulos, A., and Summers, R. J. (2011) Quantification of functional selectivity at the human alpha(1A)-adrenoceptor. Mol. Pharmacol. 79, 298-307
36. Li, J. G., Luo, L. Y., Krupnick, J. G., Benovic, J. L., and Liu-Chen, L. Y. (1999) U50, 488H-induced internalization of the human kappa opioid receptor involves a beta-arrestin-and dynamin-dependent mechanism. Kappa receptor internalization is not required for mitogen-activated protein kinase activation. J. Biol. Chem. 274, 12087-12094
37. Bohn, L. M. (2009) Selectivity for G protein-or arrestin-mediated signaling, in Functional Selectivity ofGProtein-Coupled Receptor Ligands (Neve, K., ed) 1st Ed., pp. 71-85, Humana Press, Totowa, NJ
38. Cowen, D. S., Johnson-Farley, N. N., and Travkina, T. (2005) 5-HT receptors couple to activation of Akt, but not extracellular-regulated kinase (ERK), in cultured hippocampal neurons. J. Neurochem. 93, 910-917
39. Waldhoer, M., Fong, J., Jones, R. M., Lunzer, M. M., Sharma, S. K., Kostenis, E., Portoghese, P. S., and Whistler, J. L. (2005)Aheterodimer- selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc. Natl. Acad. Sci. U.S.A. 102, 9050-9055
40. Kostenis, E. (2001) Is Galpha16 the optimal tool for fishing ligands of orphan G-protein-coupled receptors? Trends Pharmacol. Sci. 22, 560-564
41. Bohn, L. M., and McDonald, P. H. (2010) Seeking ligand bias: assessing GPCR coupling to beta-arrestins for drug discovery. Drug Discov. Today Technol. 7, e37-e42